KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oscar Health (OSCR) Consolidated Net Income (2020 - 2025)

Oscar Health's Consolidated Net Income history spans 6 years, with the latest figure at -$352.4 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 129.92% year-over-year to -$352.4 million; the TTM value through Dec 2025 reached -$442.9 million, down 1795.58%, while the annual FY2025 figure was -$442.9 million, 1795.58% down from the prior year.
  • Consolidated Net Income reached -$352.4 million in Q4 2025 per OSCR's latest filing, down from -$137.5 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $275.5 million in Q1 2025 to a low of -$352.4 million in Q4 2025.
  • Average Consolidated Net Income over 5 years is -$93.4 million, with a median of -$100.5 million recorded in 2021.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 547.87% in 2024, then tumbled 505.76% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at -$197.7 million in 2021, then decreased by 14.57% to -$226.6 million in 2022, then soared by 33.86% to -$149.8 million in 2023, then decreased by 2.3% to -$153.3 million in 2024, then plummeted by 129.92% to -$352.4 million in 2025.
  • Per Business Quant, the three most recent readings for OSCR's Consolidated Net Income are -$352.4 million (Q4 2025), -$137.5 million (Q3 2025), and -$228.5 million (Q2 2025).